Y Intercept Hong Kong Ltd Sells 10,068 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Y Intercept Hong Kong Ltd cut its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 79.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 2,631 shares of the specialty pharmaceutical company’s stock after selling 10,068 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Jazz Pharmaceuticals were worth $324,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of JAZZ. UMB Bank n.a. grew its holdings in shares of Jazz Pharmaceuticals by 70.9% during the fourth quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock worth $38,000 after buying an additional 129 shares in the last quarter. Itau Unibanco Holding S.A. boosted its position in Jazz Pharmaceuticals by 63.2% during the third quarter. Itau Unibanco Holding S.A. now owns 444 shares of the specialty pharmaceutical company’s stock valued at $49,000 after purchasing an additional 172 shares during the last quarter. GAMMA Investing LLC boosted its position in Jazz Pharmaceuticals by 49.8% during the fourth quarter. GAMMA Investing LLC now owns 620 shares of the specialty pharmaceutical company’s stock valued at $76,000 after purchasing an additional 206 shares during the last quarter. Venturi Wealth Management LLC boosted its position in Jazz Pharmaceuticals by 577.0% during the third quarter. Venturi Wealth Management LLC now owns 826 shares of the specialty pharmaceutical company’s stock valued at $92,000 after purchasing an additional 704 shares during the last quarter. Finally, Versant Capital Management Inc boosted its position in Jazz Pharmaceuticals by 56.7% during the fourth quarter. Versant Capital Management Inc now owns 967 shares of the specialty pharmaceutical company’s stock valued at $119,000 after purchasing an additional 350 shares during the last quarter. 89.14% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CAO Patricia Carr sold 4,813 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $144.42, for a total transaction of $695,093.46. Following the completion of the sale, the chief accounting officer now directly owns 8,237 shares of the company’s stock, valued at approximately $1,189,587.54. This trade represents a 36.88 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Bruce C. Cozadd sold 1,500 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $122.31, for a total value of $183,465.00. Following the sale, the chief executive officer now directly owns 439,744 shares of the company’s stock, valued at approximately $53,785,088.64. The trade was a 0.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 18,113 shares of company stock valued at $2,551,834. Insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Stock Performance

NASDAQ:JAZZ opened at $140.22 on Tuesday. The stock has a market cap of $8.52 billion, a P/E ratio of 19.75, a PEG ratio of 1.04 and a beta of 0.56. The stock has a 50 day simple moving average of $127.01 and a 200 day simple moving average of $119.37. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals plc has a 1-year low of $99.06 and a 1-year high of $148.06.

Analysts Set New Price Targets

Several research analysts recently commented on JAZZ shares. Morgan Stanley raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $140.00 to $175.00 in a research report on Thursday, December 12th. Robert W. Baird increased their price target on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an “outperform” rating in a research report on Monday, November 18th. Royal Bank of Canada reduced their price target on Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating for the company in a research report on Wednesday, February 26th. Wells Fargo & Company raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $130.00 to $170.00 in a research report on Thursday, February 13th. Finally, Needham & Company LLC raised their price objective on Jazz Pharmaceuticals from $205.00 to $210.00 and gave the company a “buy” rating in a research report on Wednesday, February 26th. Two investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Jazz Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $182.47.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.